

Driving Forces and Growth Potential: Insights into the Spinal Muscular Atrophy Treatment Market | CAGR of 6.8% 2023-2032

PORTLAND, OREGON, UNITED STATES, March 20, 2024 /EINPresswire.com/ --

An increase in the prevalence of spinal muscular atrophy, a rise in pipeline drugs, key strategies adopted by key players, and an increase in awareness regarding the treatment of spinal muscular atrophy drives the spinal muscular atrophy treatment market growth. "According to the report, the [global spinal muscular atrophy treatment industry](#) generated \$4.3 billion in 2022, and is anticipated to generate \$8.4 billion by 2032, witnessing a CAGR of 6.8% from 2023 to 2032."



Request Sample of the Report - <https://www.alliedmarketresearch.com/request-sample/107628>

Increase in prevalence of spinal muscular atrophy, initiatives by government organizations, and increase in the demand for SMA drugs for the treatment of spinal muscular atrophy drive the growth of the global spinal muscular atrophy treatment market. However, the high cost of the SMA drugs is hampering the spinal muscular atrophy treatment market growth. On the contrary, the increase in R&D activities are expected to offer remunerative opportunities for expansion of the spinal muscular atrophy treatment market during the forecast period.

Rise in demand for effective treatments for spinal muscular atrophy, pharmaceutical companies are investing more in R&D activities to create new drugs and improve existing ones further support the market growth and are also the spinal muscular atrophy treatment market trends. Moreover, rise in awareness of early diagnosis and treatment for spinal muscular atrophy and increase in acceptability of spinal muscular atrophy treatment by medical practitioners contributes toward the growth of the spinal muscular atrophy treatment market forecast.

Depending on type, the spinal muscular atrophy treatment market size is classified into type 1,

type 2, and others. The type 1 segment dominated largest share in 2022 and also exhibited the highest growth during the forecast period. This is attributed to surge in population with type 1 SMA led to rise the demand for SMA drugs to treat this type of disease.

Covid-19 Scenario

COVID-19 pandemic had a negative effect on the global spinal muscular atrophy treatment market, owing to decrease in demand for spinal muscular atrophy treatment due to the reduced diagnosis and hospital visits.

In addition, many clinical trials for SMA were temporarily delayed due to the pandemic. This interruption affected the progression of R&D activities, and potentially slowed down the availability of new treatment options & limited access to experimental therapies for SMA patients which negatively impacted the market growth.

However, the market is recovering after the pandemic, and showing stable growth for spinal muscular atrophy treatment market, owing to rise in cases of SMA disease led to increase in adoption of SMA drugs to treat the disease.

Spinal Muscular Atrophy Treatment Market key segments:

Therapy Type:

- Gene Replacement Therapy
- Medication Therapy
- Physical Therapy

Age Group:

- Pediatric Patients
- Adult Patients

Severity of SMA:

- Type 1 (Infantile-Onset)
- Type 2 (Intermediate)
- Type 3 (Juvenile)
- Type 4 (Adult-Onset)

End User:

- Hospitals
- Specialty Clinics

Rehabilitation Centers
Homecare Settings

Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Procure Complete Report : <https://www.alliedmarketresearch.com/checkout-final/spinal-muscular-atrophy-treatment-market>

North America to maintain its dominance by 2032

Based on region, North America held the largest market share in terms of revenue in 2022, accounting for nearly two-fifths of the global spinal muscular atrophy treatment market revenue, owing to robust healthcare infrastructure, availability of approved spinal muscular atrophy drugs and high healthcare expenditures. However, the Asia-Pacific region is expected to witness the fastest CAGR of 7.7% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to an increase in awareness of spinal muscular atrophy, and a rise in number of people affected with spinal muscular atrophy.□

Leading Market Players: -□

Biogen
Cytokinetics
Hanugen Therapeutics
NMD Phrama A/S
Novartis AG
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Scholar Rock Holding Corporation
Beijing Jinlan Gene Technology Co., Ltd.□
Ionis Pharmaceuticals, Inc.

For Purchase Inquiry - <https://www.alliedmarketresearch.com/purchase-enquiry/107628>

Browse More Trending Reports in Healthcare Industry By AMR -

Acupuncture Needles Market: <https://www.alliedmarketresearch.com/acupuncture-needles-market>

Veterinary Medicine Market: <https://www.alliedmarketresearch.com/veterinary-medicine-market>

Implantable Insulin Pump Market: <https://www.alliedmarketresearch.com/implantable-insulin-pump-market>

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 5038946022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/697361841>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.